You just read:

CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase 2 Clinical Trial With ENMD-2076 For Fibrolamellar Carcinoma (FLC)

News provided by

CASI Pharmaceuticals, Inc.

12 May, 2016, 07:00 ET